Sequencing the human genome enables scientists to study human biology in a granular fashion and use that information to create treatments for things like cancer. Yet, of the human genomes studied so far, only 2% have been those of Africans. Yemaachi Biotech company in Ghana is addressing that through its Africa Cancer Atlas, partnering with groups across Africa to collect and study the human genomes of cancer patients across the continent. Host Marco Werman speaks to Yaw Bediako, the co-founder and CEO of Yemaachi Biotech, from his office in Accra, Ghana.
The story you just read is not locked behind a paywall because listeners and readers like you generously support our nonprofit newsroom. Now more than ever, we need your help to support our global reporting work and power the future of The World. Can we count on you?